Kinetics of Technetium-Labeled Cardiac Amyloid Radionuclide Imaging

Area of Science:

• Nuclear medicine
• Cardiology
• Radiochemistry

Background:

• Technetium-labeled bone-avid tracers are used for diagnosing transthyretin cardiac amyloidosis.
• Hydroxymethylene diphosphonate (HMDP) is an alternative to technetium-99m pyrophosphate due to supply shortages.
• Comparative kinetic data between these tracers are limited.

Purpose of the Study:

• To characterize and compare the kinetics of technetium-99m pyrophosphate and HMDP in diagnosing transthyretin cardiac amyloidosis.
• To provide quantitative data for optimizing imaging protocols and standardization.

Main Methods:

• Quantitative single-photon emission computed tomography with computed tomography (SPECT/CT) was used.
• Serial SPECT/CT imaging was performed on subjects with pyrophosphate (n=11) or HMDP (n=13).
• Kinetic parameters including standardized uptake values (SUVs) and target-to-background ratios were analyzed over time.

Main Results:

• Both tracers provided diagnostic myocardial uptake within 10 minutes.
• Myocardial SUVs decreased linearly over time for both tracers.
• HMDP showed faster blood pool clearance and higher bone uptake than pyrophosphate, leading to earlier skeletal dominance.

Conclusions:

• Both pyrophosphate and HMDP are effective for early myocardial visualization in cardiac amyloidosis.
• HMDP's distinct kinetic profile (faster blood clearance, higher bone uptake) requires consideration for image interpretation and protocol optimization.
• The study provides crucial kinetic data for standardizing quantitative SPECT/CT imaging.